STUDY OF GROWTH DIFFERENTIATION FACTOR 15 IN EGYPTIAN PATIENTS WITH BETA THALASSEMIA
(Abstract release date: 05/21/15)
EHA Library. Hamdy Mahmoud Mohamed M. 06/12/15; 102883; PB2018
Disclosure(s): cairo universitypediatric hematology
Mona Mohamed Hamdy Mahmoud Mohamed
Contributions
Contributions
Abstract
Abstract: PB2018
Type: Publication Only
Background
The thalassemia syndromes represent the most common causes of ineffective erythropoiesis. The increased but ineffective erythropoiesis resulting in tissue iron overload induces numerous endocrine diseases, hepatic cirrhosis, cardiac failure and even death. Growth Differentiation factor 15 (GDF-15) is a member of the transforming growth factor β super family. It was recently studied as a marker of ineffective erythropoiesis in different types of anemia.
Aims
Our objective was to study the serum level of GDF- 15 in β thalassemia major (TM) and thalassemia intermedia patients (TI) and to correlate it to the iron status and different clinical and laboratory parameters in these patients
Methods
twenty five thalassemia major patients (mean age of 12.08± 4.6 years) and 25 thalassemia intermedia patients (mean age of 9.3± 4.7 years) were randomly selected from the hematology clinic of the children hospital at Cairo University together with 30 age and sex matched healthy controls. All patients were subjected to thorough history taking and clinical exam. Blood samples were withdrawn for the assessment of complete blood count, liver function tests and serum ferritin. Estimation of GDF-15 level was done using ELISA technique.
Results
On comparing the level of GDF-15 among the 3 groups, it was significantly elevated in the TM group (8769.6±3560 pg/ml) versus the TI group (7090±3656 pg/ml); P< 0.05 and versus the control group (385.1±244); P< 0.05. GDF-15 showed positive correlation to the age of starting chelation among TM patients; P= 0.04 and negative correlation to the frequency of transfusion and hemoglobin level in the TI group; P= 0.001.
Summary
GDF-15 in our study represent a first step for its use as a biomarker in thalassemia patients. Future studies with large number of patients are needed to confirm this hypothesis.
Keyword(s): Thalassemia
Session topic: Publication Only
Type: Publication Only
Background
The thalassemia syndromes represent the most common causes of ineffective erythropoiesis. The increased but ineffective erythropoiesis resulting in tissue iron overload induces numerous endocrine diseases, hepatic cirrhosis, cardiac failure and even death. Growth Differentiation factor 15 (GDF-15) is a member of the transforming growth factor β super family. It was recently studied as a marker of ineffective erythropoiesis in different types of anemia.
Aims
Our objective was to study the serum level of GDF- 15 in β thalassemia major (TM) and thalassemia intermedia patients (TI) and to correlate it to the iron status and different clinical and laboratory parameters in these patients
Methods
twenty five thalassemia major patients (mean age of 12.08± 4.6 years) and 25 thalassemia intermedia patients (mean age of 9.3± 4.7 years) were randomly selected from the hematology clinic of the children hospital at Cairo University together with 30 age and sex matched healthy controls. All patients were subjected to thorough history taking and clinical exam. Blood samples were withdrawn for the assessment of complete blood count, liver function tests and serum ferritin. Estimation of GDF-15 level was done using ELISA technique.
Results
On comparing the level of GDF-15 among the 3 groups, it was significantly elevated in the TM group (8769.6±3560 pg/ml) versus the TI group (7090±3656 pg/ml); P< 0.05 and versus the control group (385.1±244); P< 0.05. GDF-15 showed positive correlation to the age of starting chelation among TM patients; P= 0.04 and negative correlation to the frequency of transfusion and hemoglobin level in the TI group; P= 0.001.
Summary
GDF-15 in our study represent a first step for its use as a biomarker in thalassemia patients. Future studies with large number of patients are needed to confirm this hypothesis.
Keyword(s): Thalassemia
Session topic: Publication Only
Abstract: PB2018
Type: Publication Only
Background
The thalassemia syndromes represent the most common causes of ineffective erythropoiesis. The increased but ineffective erythropoiesis resulting in tissue iron overload induces numerous endocrine diseases, hepatic cirrhosis, cardiac failure and even death. Growth Differentiation factor 15 (GDF-15) is a member of the transforming growth factor β super family. It was recently studied as a marker of ineffective erythropoiesis in different types of anemia.
Aims
Our objective was to study the serum level of GDF- 15 in β thalassemia major (TM) and thalassemia intermedia patients (TI) and to correlate it to the iron status and different clinical and laboratory parameters in these patients
Methods
twenty five thalassemia major patients (mean age of 12.08± 4.6 years) and 25 thalassemia intermedia patients (mean age of 9.3± 4.7 years) were randomly selected from the hematology clinic of the children hospital at Cairo University together with 30 age and sex matched healthy controls. All patients were subjected to thorough history taking and clinical exam. Blood samples were withdrawn for the assessment of complete blood count, liver function tests and serum ferritin. Estimation of GDF-15 level was done using ELISA technique.
Results
On comparing the level of GDF-15 among the 3 groups, it was significantly elevated in the TM group (8769.6±3560 pg/ml) versus the TI group (7090±3656 pg/ml); P< 0.05 and versus the control group (385.1±244); P< 0.05. GDF-15 showed positive correlation to the age of starting chelation among TM patients; P= 0.04 and negative correlation to the frequency of transfusion and hemoglobin level in the TI group; P= 0.001.
Summary
GDF-15 in our study represent a first step for its use as a biomarker in thalassemia patients. Future studies with large number of patients are needed to confirm this hypothesis.
Keyword(s): Thalassemia
Session topic: Publication Only
Type: Publication Only
Background
The thalassemia syndromes represent the most common causes of ineffective erythropoiesis. The increased but ineffective erythropoiesis resulting in tissue iron overload induces numerous endocrine diseases, hepatic cirrhosis, cardiac failure and even death. Growth Differentiation factor 15 (GDF-15) is a member of the transforming growth factor β super family. It was recently studied as a marker of ineffective erythropoiesis in different types of anemia.
Aims
Our objective was to study the serum level of GDF- 15 in β thalassemia major (TM) and thalassemia intermedia patients (TI) and to correlate it to the iron status and different clinical and laboratory parameters in these patients
Methods
twenty five thalassemia major patients (mean age of 12.08± 4.6 years) and 25 thalassemia intermedia patients (mean age of 9.3± 4.7 years) were randomly selected from the hematology clinic of the children hospital at Cairo University together with 30 age and sex matched healthy controls. All patients were subjected to thorough history taking and clinical exam. Blood samples were withdrawn for the assessment of complete blood count, liver function tests and serum ferritin. Estimation of GDF-15 level was done using ELISA technique.
Results
On comparing the level of GDF-15 among the 3 groups, it was significantly elevated in the TM group (8769.6±3560 pg/ml) versus the TI group (7090±3656 pg/ml); P< 0.05 and versus the control group (385.1±244); P< 0.05. GDF-15 showed positive correlation to the age of starting chelation among TM patients; P= 0.04 and negative correlation to the frequency of transfusion and hemoglobin level in the TI group; P= 0.001.
Summary
GDF-15 in our study represent a first step for its use as a biomarker in thalassemia patients. Future studies with large number of patients are needed to confirm this hypothesis.
Keyword(s): Thalassemia
Session topic: Publication Only
{{ help_message }}
{{filter}}